Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
- Category: More News
- Published on Wednesday, 27 February 2019 10:16
- Hits: 826
|Study of investigational personalized T-cell therapy IMA101 expanded to explore combination with anti-PDL1 antibody|
HOUSTON, TX, USA and TUEBINGEN, Germany I February 26, 2019 I Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers.
IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced / metastatic solid tumors. IMA101 is based on Immatics’ ACTolog® approach, which follows the principle of expanding target-specific endogenous T-cells, a technique pioneered by Cassian Yee, M.D., Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.
The combination trial will evaluate potential synergistic effects generated by using the investigational immunotherapies together, as atezolizumab may enhance IMA101’s ability to kill cancer cells by blocking inhibitory immune checkpoints.
The combination clinical trial, which is expected to begin later this year under an amendment to the ACTolog® IMA101-101 study protocol (Clinicaltrials.gov: NCT02876510), will be conducted at MD Anderson, led by Apostolia Tsimberidou, M.D., Ph.D., Professor of Department of Investigational Cancer Therapeutics at MD Anderson.
Stephen Eck, M.D., Ph.D., Chief Medical Officer (CMO) at Immatics US, Inc., said: “Our innovative ACTolog® process allows us to utilize a patient’s own T-cells to generate a targeted approach for treating solid tumors with increased safety and efficacy potential. We are extremely pleased that, in collaboration with our long-term partner, we are now combining this promising personalized cell therapy with atezolizumab.”
|- ENDS -|
Notes To Editors
About ACTolog® T-cell therapy
TECENTRIQ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.